Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/
MOSS!MODULARITY Injection Screw
MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.:
- Improved visualisation and access to the surgical working space;
- Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads;
- Increased surgical versatility, as surgeons can choose between different types of modular screw shafts and various tulip heads to be added to the screw shafts in-situ as and when required.
Breaking new ground, Biedermann Motech will now introduce the MOSS!MODULARITY Injection Screw to selective markets outside the U.S. Fenestrated injection pedicle screws for spinal surgery, which Biedermann Motech has been pioneering since 2003, enable the injection of bone cement through the screw to enhance fixation in compromised bone1. The new injection screw workflow allows surgeons to insert the headless screw shaft directly into the bone, using the injection adaptor as the screw inserter, and then seamlessly inject bone cement before attaching the modular tulip heads to the screw shaft. The MOSS!MODULARITY Injection Screw workflow features proprietary technology licensed from intellectual property powerhouse and recognized innovation leader Biedermann Technologies GmbH & Co. KG and will be the first of its kind worldwide.
Simultaneously, Biedermann Motech will launch the next generation of its DELTA XS ® Retractor System for advanced Transforaminal Lumbar Interbody Fusion (“TLIF”) surgery. The DELTA XS 2.0 Retractor System has been specifically developed to combine the advantages of a screw shank based retractor with the benefits of the MOSS!MODULARITY workflow and can be used in a variety of surgical techniques and approaches, from open to less invasive, microsurgical TLIF surgery.
The MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System are fully compatible with the MOSS 100 Modular Pedicle Screw System, the MOSS VRS System and the MOSS VRS MIS System for advanced posterior fixation and correction and will further strengthen these platforms for specialized spinal surgery.
Biedermann Motech will showcase the worldwide first MOSS!MODULARITY Injection Screw and the DELTA XS 2.0 Retractor System at the upcoming Eurospine Meeting in Copenhagen, Denmark.
ABOUT BIEDERMANN MOTECH & BIEDERMANN TECHNOLOGIES
Biedermann is a mid-sized, family-owned group of companies, whose roots go back to 1916. Biedermann researches, develops, manufactures, and distributes high-end implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. It is also owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 30 years, Biedermann has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field and established multiple new golden standards for spinal technologies.
For more information, please visit:
www.biedermann.com and www.biedermann-technologies.com
1 J Orthop Traumatol. 2011 Nov 8;12(4):193–199; Int J Spine Surg. 2021 Feb 26;15(1):113–118.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251019799867/en/
Contacts
transformation@biedermann.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 13:01:00 EEST | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective cooling. The outcome is less pipe clutter, and less noise for mo
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will be presented, highlighting promising antitumor activity and a generally manageable safety and tolerability profile in patients with advanced solid tumors. “The results presented at ESMO 2025 strengthen the evidence base for TEVIMBRA in lung cancer, with consistent survival ben
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 12:00:00 EEST | Press release
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EUR neffy ® , Now Available in the UK20.10.2025 11:01:00 EEST | Press release
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch
Leading Global Businesses Unite to Launch Carbon Measures20.10.2025 11:00:00 EEST | Press release
Carbon Measures, a new global coalition representing major businesses from diverse industries and geographies, launched today to establish a more accurate carbon accounting framework and drive market-based solutions to reduce emissions at the lowest cost. The coalition’s work will leverage sound science and the principles of financial accounting to help enable a ledger-based carbon accounting framework that is substantially more accurate, eliminates double counting and addresses current information gaps. By better tracking emissions through the global economy, this new framework will help businesses differentiate their products and governments make more informed policy decisions. Carbon Measures is calling for new policy that unlocks innovation, competition and the power of the market. Global carbon emissions are rising and will continue to increase unless effective, efficient and pragmatic policies are implemented. Product-level carbon intensity standards, based on verifiable data inf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom